← Oncology Approval Tracker

FDA DECISION ·

Ojjaara

momelotinib · GlaxoSmithKline

FDA approvalNew therapyMyelofibrosis
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with anemia and intermediate- or high-risk myelofibrosis, including primary disease and disease arising after polycythemia vera or essential thrombocythemia.

LAMPGEN ANALYSIS

Why it matters

The decision added a targeted option specifically for anemic patients with intermediate- or high-risk myelofibrosis.

What research teams should watch

Document risk category, baseline anemia and transfusion history alongside spleen and symptom assessments.

PRIMARY RECORDS

Sources